Journal of Advances in Medicine and Medical Research, ISSN: 2456-8899, ISSN: 2231-0614 (Past),Vol.: 23, Issue.: 12
Survey Report on Parents and Patients Related to the Use of Cannabidiol Symptomatic Epilepsy Secondary to Tuberous Sclerosis Complex (TSC) in Mexico
Carlos G. Aguirre-Velázquez1*, Mario Peral-Ríos1, Evelyn López-Guevara1 and Kenny Lemus-Roldán1 1Neuropediatría Tecnológico de Monterrey, Campus Salud Avenida Morones Prieto 3000 Pte. Col. Los Doctores, 64710 Monterrey, NL, México.
Carlos G. Aguirre-Velázquez1*, Mario Peral-Ríos1, Evelyn López-Guevara1 and Kenny Lemus-Roldán1
1Neuropediatría Tecnológico de Monterrey, Campus Salud Avenida Morones Prieto 3000 Pte. Col. Los Doctores, 64710 Monterrey, NL, México.
(1) Thomas I. Nathaniel, University of South Carolina, School of Medicine-Greenville, Greenville, USA.
(1) Elias Ernesto Aguirre Siancas, Universidad Nacional Mayor de San Marcos, Lima, Perú.
(2) Ekaterina Viteva, Medical University – Plovdiv, Bulgaria.
Complete Peer review History: http://www.sciencedomain.org/review-history/21181
A descriptive observational study using a structured survey was circulated through Facebook networks that comprised of parents of children and patients with tuberous sclerosis complex and epilepsy on conventional or medicinal cannabis/cannabidiol (CBD) treatment. Of 105 surveys, 58 were obtained by self-selection and 10 from patients treated with CBD. Forty-seven children and 11 adults, 52% male, 48% female, were included. Epileptic syndromes were present in 70.6% of the cases of which Lennox-Gastaut Syndrome (LGS) was in 20, West syndrome (WS) in 20, and epilepsy with myoclonic-astatic crises (MAE) in 6. Refractory epilepsy (RE) was present in 22 (38%) cases. Ten patients (17.2%) underwent CBD treatment; seizures decreased for 7 patients, with significant decreases in 6 and minor decreases in 1. No effect was seen in 3 patients and there were no seizure-free cases or cases where the seizure worsened. Improvement in quality of life parameters were observed. Mild adverse events were observed in 4 cases (40%). Monthly treatment costs ranged from $300 pesos with CBD to $35,000 pesos with everolimus. Average monthly costs with CBD were $4,039 ± 2,530 pesos. Patient and parent reports suggest medicinal cannabis is a therapeutic option offering improvement in seizures and quality of life at a moderate cost.
Cannabidiol; tuberous sclerosis complex; epilepsy.
Full Article - PDF Page 1-8
DOI : 10.9734/JAMMR/2017/36585Review History Comments